Financial Performance - Total revenue for Q2 2025 was $614 million, a decrease of 4% year-over-year on a constant currency basis[5] - Adjusted EBITDA for Q2 2025 was $107 million, resulting in a 17% margin[5] - Adjusted diluted EPS for Q2 2025 was $0.12, a 271% increase year-over-year[6] - Year-to-date total revenue was $131 billion, a decrease of 2% year-over-year on a constant currency basis[11] - Year-to-date adjusted EBITDA was $267 million, resulting in a 20% margin[11] - Year-to-date adjusted diluted EPS was $086, a 132% increase year-over-year[11] Revenue Breakdown - North America accounted for 57% of total revenue[7] - Recurring revenue represented 82% of the total revenue[7] - Labs business unit contributed 51% of the total revenue[7] Cash Flow and Balance Sheet - Q2 2025 adjusted free cash flow was negative $32 million[15] - Year-to-date adjusted free cash flow was $15 million[15] - Total debt was $26 billion[15] Financial Guidance for FY 2025 - Total revenues are projected to be between $260 billion and $281 billion[17] - Adjusted EBITDA is expected to be between $575 million and $615 million, with a margin of 22%[17] - Adjusted diluted EPS is projected to be between $207 and $257[17]

Core Insights - QuidelOrtho Corporation reported a total revenue of $614 million for Q2 2025, a decrease of 3.6% compared to $637 million in the prior year period, primarily due to lower COVID-19 and Donor Screening revenue [3][14] - The company achieved adjusted diluted EPS of $0.12, compared to an adjusted diluted loss per share of ($0.07) in the prior year period, indicating a significant improvement in profitability metrics [5][14] - The company reiterated its full-year 2025 financial guidance, projecting total revenues between $2.60 billion and $2.81 billion and adjusted EBITDA between $575 million and $615 million [7][14] Financial Performance - Total revenue for Q2 2025 was $614 million, down from $637 million in Q2 2024, with a notable decrease in COVID-19 related revenue [3][14] - GAAP diluted loss per share was $3.77, compared to a loss of $2.20 in the prior year, reflecting increased operational challenges [4][14] - Adjusted EBITDA for Q2 2025 was $107 million, up from $90 million in the prior year, with an adjusted EBITDA margin of 17%, a 330 basis point improvement [5][14] Operational Highlights - The company achieved $100 million in annualized cost savings through various initiatives, which contributed to improved margins [2][14] - Labs revenue grew by 4% as reported and 5% in constant currency, indicating strong performance in this segment [14] - The company announced its intention to acquire LEX Diagnostics and initiated a major manufacturing site consolidation [2][14] Revenue Breakdown - Non-respiratory revenue was $567 million, a decrease of 2% year-over-year, while excluding Donor Screening, it grew by 1% in constant currency [14][25] - Respiratory revenue was $47 million, a 20% decrease primarily driven by lower COVID-19 revenue [14] - Immunohematology revenue grew by 4% as reported and 3% in constant currency, showcasing resilience in this area [14] Guidance and Future Outlook - The company maintains its fiscal 2025 guidance, expecting total revenues of $2.60 billion to $2.81 billion and adjusted diluted EPS between $2.07 and $2.57 [7][14] - The anticipated impact of foreign currency exchange is expected to be neutral for the full year based on rates as of July 27, 2025 [7][14] - The company is focused on delivering sustainable value over time for shareholders, customers, and employees [2][14]

Core Insights - QuidelOrtho received three awards and top rankings in the 2025 IMV ServiceTrak Awards, highlighting excellence in customer satisfaction within the diagnostics industry [1][8] - The company achieved a 17-point increase in Net Promoter Score (NPS), indicating significant improvements in customer loyalty and satisfaction [2][8] - QuidelOrtho's success is attributed to investments in customer experience initiatives and employee development, enhancing product quality and service [3][4] Awards and Rankings - QuidelOrtho was recognized for the best overall system performance in both Chemistry and Integrated Systems categories [8] - The company achieved the highest rankings in several key areas, including: - 1 Overall Net Promoter Score (NPS) by Manufacturer - 1 Overall Manufacturer Performance - 1 Overall Service Engineer Performance - 1 Overall Training Performance [8][9] Customer-Centric Approach - The company prioritizes customer beliefs and values, focusing on delivering solutions that enhance laboratory efficiency and outcomes [3][4] - QuidelOrtho's commitment to ongoing innovation and customer-focused solutions is evident in their QuidelOrthoCQ™ offerings, which aim to support customer success [5][6]

Core Insights - The podcast episode discusses the increasing complexities of substance use detection and care in emergency departments, emphasizing the need for rapid diagnostic testing to prevent drug overdose deaths [3][8] - Vonda McAllister, Director of Global Product Management at QuidelOrtho, highlights the importance of continuous monitoring and comprehensive toxicology screening in addressing the crisis of drug overdoses [5] Industry Trends - There is a rising prevalence of potent synthetic drugs such as fentanyl, xylazine, and nitazines, which complicates overdose presentations [8] - The limitations of Narcan (naloxone) are becoming evident, with a growing need for repeated doses due to the potency of new opioid analogs [8] - California's "Tyler's Law" mandates fentanyl testing in suspected overdose cases, reflecting a legislative response to the crisis [8] Company Overview - QuidelOrtho Corporation is a global provider of innovative diagnostic testing solutions, focusing on various health areas including infectious diseases and cardiac biomarkers [7] - The company aims to transform diagnostics into a healthier future through science, innovation, and accessibility [7]

Core Viewpoint - QuidelOrtho Corporation will report its financial results for the second quarter of 2025 on August 5, 2025, after market close [1] Financial Results Announcement - The financial results will be discussed in a conference call scheduled for 2:00 p.m. PT / 5:00 p.m. ET on the same day [2] - Interested parties can access the call via the Company's Investor Relations page or by phone using specific dial-in numbers [2] Replay Availability - A replay of the conference call will be available shortly after the event on the Company's Investor Relations page [3] Company Overview - QuidelOrtho Corporation is a leader in in vitro diagnostics, focusing on innovative solutions that enhance understanding and action in healthcare [4] - The company specializes in immunoassay and molecular testing, clinical chemistry, and transfusion medicine, providing reliable diagnostics across various settings [4][5]

Group 1 - QuidelOrtho Corporation is a leader in in vitro diagnostics, focusing on transforming data into actionable insights for healthcare [4][5]. - The company specializes in immunoassay and molecular testing, clinical chemistry, and transfusion medicine, providing reliable diagnostics across various settings [4]. - QuidelOrtho emphasizes innovation and collaboration with global healthcare customers to enhance diagnostic solutions [5]. Group 2 - A session titled "Real Labs, Real Decisions with Actionable Six Sigma Metrics" is scheduled for July 29, 2025, at the McCormick Convention Center in Chicago [1]. - The session will feature a panel of experts, including Dr. Jared Jaeger from QuidelOrtho and other professionals from notable institutions [2]. - Attendees can register for the session or access a recording if unable to attend [3].

Core Insights - The collaboration between QuidelOrtho and BÜHLMANN Laboratories AG focuses on addressing key healthcare trends such as non-invasive diagnostic tools, cost-effective healthcare solutions, and the emphasis on gastrointestinal and pancreatic health [1][4] - The fCAL and fPELA turbo assays represent significant advancements in the diagnosis of inflammatory bowel disease (IBD) and pancreatic insufficiency, providing fast results that enhance patient care [2][4] - The integration of CALEX Cap technology simplifies sample extraction and preparation, improving operational efficiency and clinical accuracy [3][4] Company Overview - QuidelOrtho Corporation is a leader in in vitro diagnostics, offering solutions that transform data into actionable insights across various healthcare settings [6][7] - BÜHLMANN Laboratories AG has been developing innovative in-vitro diagnostic assays for nearly 50 years, focusing on chemistry and immunological testing [9] Product Features - The fCAL and fPELA turbo assays provide rapid results in less than 10 minutes, with a 90-day on-analyzer stability and compatibility with VITROS Automation Solutions [8] - The collaboration enhances flexibility in sample handling and processing, catering to a wide variety of sample collection methods [4]

Company Leadership and Strategy - Burek has been appointed as SVP of Global Quality, focusing on a streamlined global approach to enhance product quality and operational effectiveness [1] - Gadaleta will serve as SVP of Clinical and Regulatory Affairs, leading global clinical trial strategy and regulatory submissions, leveraging his extensive experience in navigating complex global regulations [2] - Sergio's addition to the team is expected to guide innovations through clinical and regulatory pathways, emphasizing the company's commitment to scientific excellence and customer trust [3] Company Overview - QuidelOrtho Corporation is a leader in in vitro diagnostics, developing intelligent solutions that transform data into actionable insights for healthcare [5] - The company specializes in immunoassay and molecular testing, clinical chemistry, and transfusion medicine, providing fast and reliable diagnostics across various settings [5] - QuidelOrtho aims to advance diagnostics by connecting insights and solutions, facilitating informed decision-making in healthcare [6]

Core Insights - The article emphasizes the importance of the Zacks Rank in identifying strong stocks through earnings estimates and revisions, while also acknowledging that investors have their own strategies [1] - Value investing is highlighted as a popular method for finding great stocks across various market conditions, utilizing established valuation metrics [2] - The Style Scores system is introduced, particularly the "Value" category, which helps value investors identify stocks with high Zacks Ranks and "A" grades for Value [3] Company Overview: QuidelOrtho (QDEL) - QuidelOrtho (QDEL) currently holds a Zacks Rank of 2 (Buy) and an A grade for Value, indicating strong potential for value investors [4] - The stock is trading at a P/E ratio of 10.75, significantly lower than the industry average P/E of 21.17, suggesting it may be undervalued [4] - Over the past 12 months, QDEL's Forward P/E has fluctuated between a high of 25.36 and a low of 9.36, with a median of 14.18, indicating variability in market perception [4] - The P/S ratio for QDEL is 0.74, compared to the industry average P/S of 1.44, further supporting the notion of undervaluation [5] - These metrics collectively suggest that QuidelOrtho is likely undervalued and presents a strong earnings outlook, making it an attractive value stock at this time [6]

Core Viewpoint - QuidelOrtho (QDEL) has been upgraded to a Zacks Rank 2 (Buy) due to an upward trend in earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Impact - The Zacks rating system is based on changes in earnings estimates, which are closely correlated with near-term stock price movements [4][6]. - Institutional investors often rely on earnings estimates to determine the fair value of a company's shares, leading to significant stock price movements when estimates are revised [4]. Company Performance and Outlook - The upgrade indicates an improvement in QuidelOrtho's underlying business, suggesting that investors may respond positively by driving the stock price higher [5][10]. - For the fiscal year ending December 2025, QuidelOrtho is expected to earn $2.39 per share, with a 4.6% increase in the Zacks Consensus Estimate over the past three months [8]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with a strong historical performance, particularly for Zacks Rank 1 stocks, which have generated an average annual return of +25% since 1988 [7][9]. - QuidelOrtho's upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [10].